Literature DB >> 18945882

Real-time in vivo green fluorescent protein imaging of a murine leishmaniasis model as a new tool for Leishmania vaccine and drug discovery.

Sanjay R Mehta1, Robert Huang, Meng Yang, Xing-Quan Zhang, Bala Kolli, Kwang-Poo Chang, Robert M Hoffman, Yasuyuki Goto, Roberto Badaro, Robert T Schooley.   

Abstract

Leishmania species are obligate intracellular protozoan parasites that cause a broad spectrum of clinical diseases in mammalian hosts. The most frequently used approach to quantify parasites in murine model systems is based on thickness measurements of the footpad or ear after experimental infection. To overcome the limitations of this method, we used a Leishmania mutant episomally transfected with enhanced green fluorescent protein, enabling in vivo real-time whole-body fluorescence imaging, to follow the progression of Leishmania infection in parasitized tissues. Fluorescence correlated with the number of Leishmania parasites in the tissue and demonstrated the real-time efficacy of a therapeutic vaccine. This approach provides several substantial advantages over currently available animal model systems for the in vivo study of immunopathogenesis, prevention, and therapy of leishmaniasis. These include improvements in sensitivity and the ability to acquire real-time data on progression and spread of the infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18945882      PMCID: PMC2593180          DOI: 10.1128/CVI.00270-08

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  26 in total

1.  Expression of green fluorescent protein as a marker for effects of antileishmanial compounds in vitro.

Authors:  S W Kamau; F Grimm; A B Hehl
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

2.  Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases.

Authors:  M Yang; E Baranov; P Jiang; F X Sun; X M Li; L Li; S Hasegawa; M Bouvet; M Al-Tuwaijri; T Chishima; H Shimada; A R Moossa; S Penman; R M Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

Review 3.  Experimental cutaneous Leishmaniasis: a powerful model to study in vivo the mechanisms underlying genetic differences in Th subset differentiation.

Authors:  Jacques Louis; Alain Gumy; Heike Voigt; Martin Röcken; Pascal Launois
Journal:  Eur J Dermatol       Date:  2002 Jul-Aug       Impact factor: 3.328

4.  Genomic and proteomic expression analysis of Leishmania promastigote and amastigote life stages: the Leishmania genome is constitutively expressed.

Authors:  Kirk Leifso; Gabriela Cohen-Freue; Nisha Dogra; Angus Murray; W Robert McMaster
Journal:  Mol Biochem Parasitol       Date:  2006-12-08       Impact factor: 1.759

5.  Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis.

Authors:  Henry W Murray; Elaine B Brooks; Jennifer L DeVecchio; Frederick P Heinzel
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

6.  Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.

Authors:  Rhea N Coler; Yasir A W Skeiky; Karen Bernards; Kay Greeson; Darrick Carter; Charisa D Cornellison; Farrokh Modabber; Antonio Campos-Neto; Steven G Reed
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

Review 7.  Re-examination of the immunosuppressive mechanisms mediating non-cure of Leishmania infection in mice.

Authors:  David Sacks; Charles Anderson
Journal:  Immunol Rev       Date:  2004-10       Impact factor: 12.988

8.  A microplate assay for Leishmania amazonensis promastigotes expressing multimeric green fluorescent protein.

Authors:  Marion Man-Ying Chan; J Chloe Bulinski; Kwang-Poo Chang; Dunne Fong
Journal:  Parasitol Res       Date:  2002-10-23       Impact factor: 2.289

9.  Applications of recombinant Leishmania amazonensis expressing egfp or the beta-galactosidase gene for drug screening and histopathological analysis.

Authors:  Takahiro Okuno; Yasuyuki Goto; Yoshitsugu Matsumoto; Haruki Otsuka; Yasunobu Matsumoto
Journal:  Exp Anim       Date:  2003-04

10.  Intradermal inoculations of low doses of Leishmania major and Leishmania amazonensis metacyclic promastigotes induce different immunoparasitic processes and status of protection in BALB/c mice.

Authors:  Nathalie Courret; Thierry Lang; Geneviève Milon; Jean Claude Antoine
Journal:  Int J Parasitol       Date:  2003-10       Impact factor: 3.981

View more
  21 in total

Review 1.  Noninvasive biophotonic imaging for studies of infectious disease.

Authors:  Nuria Andreu; Andrea Zelmer; Siouxsie Wiles
Journal:  FEMS Microbiol Rev       Date:  2010-10-19       Impact factor: 16.408

2.  In vivo fluorescence imaging of muscle cell regeneration by transplanted EGFP-labeled myoblasts.

Authors:  Xiaoyin Xu; Zhong Yang; Qiang Liu; Yaming Wang
Journal:  Mol Ther       Date:  2010-02-02       Impact factor: 11.454

3.  Exogenous Signaling Molecules Released from Aptamer-Functionalized Hydrogels Promote the Survival of Mesenchymal Stem Cell Spheroids.

Authors:  Nan Zhao; James Coyne; Lidya Abune; Peng Shi; Xiaojun Lance Lian; Ge Zhang; Yong Wang
Journal:  ACS Appl Mater Interfaces       Date:  2020-05-21       Impact factor: 9.229

4.  In vitro screening test using Leishmania promastigotes stably expressing mCherry protein.

Authors:  Paola Vacchina; Miguel A Morales
Journal:  Antimicrob Agents Chemother       Date:  2014-01-06       Impact factor: 5.191

5.  Monitoring the efficacy of antimicrobial photodynamic therapy in a murine model of cutaneous leishmaniasis using L. major expressing GFP.

Authors:  Elena Latorre-Esteves; Oleg E Akilov; Prakash Rai; Stephen M Beverley; Tayyaba Hasan
Journal:  J Biophotonics       Date:  2010-06       Impact factor: 3.207

6.  Expression of fluorescent proteins in bifidobacteria for analysis of host-microbe interactions.

Authors:  Verena Grimm; Marita Gleinser; Caroline Neu; Daria Zhurina; Christian U Riedel
Journal:  Appl Environ Microbiol       Date:  2014-02-28       Impact factor: 4.792

7.  An alternative in vitro drug screening test using Leishmania amazonensis transfected with red fluorescent protein.

Authors:  Marcele N Rocha; Célia M Corrêa; Maria N Melo; Stephen M Beverley; Olindo Assis Martins-Filho; Ana Paula Madureira; Rodrigo P Soares
Journal:  Diagn Microbiol Infect Dis       Date:  2013-01-10       Impact factor: 2.803

Review 8.  Imaging of the host/parasite interplay in cutaneous leishmaniasis.

Authors:  Owain R Millington; Elmarie Myburgh; Jeremy C Mottram; James Alexander
Journal:  Exp Parasitol       Date:  2010-05-23       Impact factor: 2.011

9.  Stage-regulated GFP Expression in Trypanosoma cruzi: applications from host-parasite interactions to drug screening.

Authors:  Rafael Luis Kessler; Daniela Fiori Gradia; Rita de Cássia Pontello Rampazzo; Édio Elígio Lourenço; Nilson José Fidêncio; Lauro Manhaes; Christian Macagnan Probst; Andréa Rodrigues Ávila; Stenio Perdigão Fragoso
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

10.  Appraisal of a Leishmania major strain stably expressing mCherry fluorescent protein for both in vitro and in vivo studies of potential drugs and vaccine against cutaneous leishmaniasis.

Authors:  Estefania Calvo-Álvarez; Nestor Adrian Guerrero; Raquel Alvarez-Velilla; Christopher Fernández Prada; Jose María Requena; Carmen Punzón; Miguel Ángel Llamas; Francisco J Arévalo; Luis Rivas; Manuel Fresno; Yolanda Pérez-Pertejo; Rafael Balaña-Fouce; Rosa M Reguera
Journal:  PLoS Negl Trop Dis       Date:  2012-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.